Against this backdrop, Biogen lifted its estimates for adjusted diluted earnings per share to between $15.50 to $16.00, up ...

Eisai (ESALF) and Eli Lilly (LLY) post new long-term data for thier Alzheimer's drugs Leqembi and Kisunla, respectively. Read more here.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher ...

Two-Year Real-World Study of LEQEMBI(R) in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025 </str ...

Biogen (NASDAQ:BIIB) is scheduled to announce Q2 earnings results on Thursday, July 31st, before market open. The consensus EPS Estimate is $3.88 (-3.5% Y/Y) and the consensus Revenue Estimate is ...

Wednesday closed down -0.12%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.38%, and the Nasdaq 100 Index ...

Four Years of Lecanemab Therapy Helped Patients Slow the Progression of AD and Remain in the Early Stages of AD Longer Compared to AD’s Natural Course ...

Analysts have given Biogen a total of 11 ratings, with the consensus rating being Outperform. The average one-year price target is $187.27, indicating a potential 46.42% upside.

Alkermes just reported Q2 results, with progress around revenue growth from its product portfolio and some pipeline progress.

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today published the preliminary global revenue for Leqembi during the second quarter 2025, in conjunction with their partner Biogen's ...